Bioavailable central nervous system disease-modifying therapies for multiple sclerosis
Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous system play a critical role. To our knowledge, alemtuzumab, fumarates (dimethyl, d...
Main Authors: | Hans-Peter Hartung, Bruce A.C. Cree, Michael Barnett, Sven G. Meuth, Amit Bar-Or, Lawrence Steinman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1290666/full |
Similar Items
-
Single-Nucleus RNA-seq of Normal-Appearing Brain Regions in Relapsing-Remitting vs. Secondary Progressive Multiple Sclerosis: Implications for the Efficacy of Fingolimod
by: Yasuyuki Kihara, et al.
Published: (2022-06-01) -
Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review
by: Vincenzo Carlomagno, et al.
Published: (2023-07-01) -
Ozanimod: A Practical Review for Nurses and Advanced Practice Providers
by: Rubin M, et al.
Published: (2024-02-01) -
Does Siponimod Exert Direct Effects in the Central Nervous System?
by: Markus Kipp
Published: (2020-07-01) -
Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
by: Grace Lassiter, et al.
Published: (2020-12-01)